Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1976 Jun;73(6):2106–2108. doi: 10.1073/pnas.73.6.2106

Rheumatoid factor and tumor-host interaction.

J J Twomey, R D Rossen, V M Lewis, A H Laughter, C C Douglass
PMCID: PMC430458  PMID: 1064877

Abstract

In this survey for rheumatoid factor (RF) seropositivity on patients with neoplasms, an 85% rate of positive screening tests was recorded under certain circumstances. This high rate of RF seropositivity occurred after irradiation and/or chemotherapy of breast and lung cancers. Treated patients with breast cancers who had no evidence of residual tumor had an 89% rate of positive RF tests. Conversely, the incidence of RF seropositivity was low among untreated patients with similar tumors and treated patients with glioblastomas or multiple myeloma. The administration of cytotoxic drugs (e.g., azathiprene) was not itself associated with RF production even in renal allograft recipients. The data indicate that RF production occurs frequently after therapy of certain tumors and suggest that in these circumstances RF may be an expression of tumor-host interaction.

Full text

PDF
2106

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashe W. K., Daniels C. A., Scott G. S., Notkins A. L. Interaction of rheumatoid factor with infectious herpes simplex virus-antibody complexes. Science. 1971 Apr 9;172(3979):176–177. doi: 10.1126/science.172.3979.176. [DOI] [PubMed] [Google Scholar]
  2. Chase M. W. Delayed-type hypersensitivity and the immunology of Hodgkin's disease, with a parallel examination of sarcoidosis. Cancer Res. 1966 Jun;26(6):1097–1120. [PubMed] [Google Scholar]
  3. HEIMER R., LEVIN F. M., RUDD E. GLOBULINS RESEMBLING RHEUMATOID FACTOR IN SERUM OF THE AGED. Am J Med. 1963 Aug;35:175–181. doi: 10.1016/0002-9343(63)90208-0. [DOI] [PubMed] [Google Scholar]
  4. Hirano A., Dembitzer H. M., Becker N. H., Levine S., Zimmerman H. M. Fine structural alterations of the blood-brain barrier in experimental allergic encephalomyelitis. J Neuropathol Exp Neurol. 1970 Jul;29(3):432–440. doi: 10.1097/00005072-197007000-00007. [DOI] [PubMed] [Google Scholar]
  5. Hurri L., Perttala Y. Observations on non-specific Waaler-Rose and latex reactions in cancer patients. Ann Med Intern Fenn. 1965;54(4):181–183. [PubMed] [Google Scholar]
  6. Jacqueline F., Podliachouk L., Eyquem A. Facteurs rhumatoïdes et substances anti-Gm au cours de la vieillesse. Ann Inst Pasteur (Paris) 1965 Nov;(Suppl):48–57. [PubMed] [Google Scholar]
  7. Johnson A. H., Rossen R. D., Hersh E. M., Farrow S. S., Butler W. T., Suki W. N. Blastogenic suppression and alloantibody activity of sera from renal allograft recipients. J Clin Invest. 1974 Jan;53(1):270–278. doi: 10.1172/JCI107547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Johnson P. M., Watkins J., Wolborow E. J. Antiglobulin production to altered IgG in rheumatoid arthritis. Lancet. 1975 Mar 15;1(7907):611–614. doi: 10.1016/s0140-6736(75)91888-7. [DOI] [PubMed] [Google Scholar]
  9. KUNKEL H. G., FRANKLIN E. C., MULLER-EBERHARD H. J. Studies on the isolation and characterization of the "rheumatoid factor". J Clin Invest. 1959 Feb;38(2):424–434. doi: 10.1172/JCI103817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Klein W. J., Jr Lymphocyte-mediated cytotoxicity in vitro. Effect of enhancing antisera. J Exp Med. 1971 Nov 1;134(5):1238–1252. doi: 10.1084/jem.134.5.1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McDuffie F. C., Brumfield H. W. Effect of rheumatoid factor on complement-mediated phagocytosis. J Clin Invest. 1972 Dec;51(12):3007–3014. doi: 10.1172/JCI107128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Onoue K., Tanigaki N., Yagi Y., Pressman D. IgM and IgG anti-hapten antibody: hemolytic, hemagglutinating and precipitating activity. Proc Soc Exp Biol Med. 1965 Nov;120(2):340–346. doi: 10.3181/00379727-120-30531. [DOI] [PubMed] [Google Scholar]
  13. ROBBINS J. B., KENNY K., SUTER E. THE ISOLATION AND BIOLOGICAL ACTIVITIES OF RABBIT GAMMA M- AND GAMMA G-ANTI-SALMONELLA TYPHIMURIUM ANTIBODIES. J Exp Med. 1965 Aug 1;122:385–402. doi: 10.1084/jem.122.2.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schmid F. R., Roitt I. M., Rocha M. J. Complement fixation by a two-component antibody system: immunoglobulin G and immunoglobulin M anti-globulin (rheumatoid factor). Parodoxical effect related to immunoglobulin G concentration. J Exp Med. 1970 Oct 1;132(4):673–693. doi: 10.1084/jem.132.4.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sjögren H. O., Hellström I., Bansal S. C., Warner G. A., Hellström K. E. Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int J Cancer. 1972 Mar 15;9(2):274–283. doi: 10.1002/ijc.2910090205. [DOI] [PubMed] [Google Scholar]
  17. Thunold S., Abeyounis C. J., Milgrom F., Witebsky E. Anti-gamma-globulin factors in serum and tissue of cancer patients. Int Arch Allergy Appl Immunol. 1970;38(3):260–268. doi: 10.1159/000230279. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES